← All diseases Infectious diseases

Chronic hepatitis C

Automatically tracked from PubMed and ClinicalTrials.gov, newest on top. Nothing ever disappears here: what you keep in your favorites remains findable. · RSS feed of this disease · only the strongest evidence

Search Period All yearsLast 12 monthsLast 5 years Topic All topicsGeneralNutrition and dietAlternative treatment methods Type of research Any type of researchHighest evidence only (76)Meta-analysis (20)Treatment guideline (4)Phase 3 study (24)Randomized trial (14)Systematic review (14)Clinical trial (680)Review article (146)Early study (phase 1 or 2) (11)Case report (85)Laboratory or animal study (8)Commentary or editorial (53)Retracted publication (2) Studies currently recruiting participants only (15)

Filter

Publications and studies (1942)

• Determinants of liver stiffness assessed by transient elastography in transfusion-dependent thalassemia. (2026/08/05) ♡
• A machine learning-derived aging-related gene signature for diagnosing HCV cirrhosis: Insights into immune microenvironment and therapeutic targets. (2026/08/03) ♡
• Serum Agalactosyl IgG Predicts Hepatocellular Carcinoma and All-Cause Mortality After SVR in Advanced Chronic Hepatitis C. (2026/08/02) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. HCV micro-elimination in diabetes care: A multicenter, prospective quality improvement program in Taiwan. (2026/08/01) ♡
• Randomized researchiParticipants were divided into groups by lottery and compared with each other. This reduces the chance that a difference is due to something other than the treatment. A Multicenter, open-label, randomized, non-inferiority trial of 8 versus 12 weeks of sofosbuvir/ravidasvir treatment in non-cirrhotic patients with chronic hepatitis C virus infection (EASE trial). (2026/08/01) ♡
• Chronic Viral Hepatitis With MASLD: Implications for Clinical and Patient-Reported Outcomes. (2026/08/01) ♡
• Nationwide Socioeconomic Evaluation of Direct-Acting Antivirals for Chronic Hepatitis C Virus Infection in Japan Between 2014 and 2023. (2026/08/01) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Gut Microbiota, Immunity, and Metabolism in the Progression From Chronic Liver Disease to Hepatocellular Carcinoma. (2026/08/01) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Cumulative Metformin Use and Hepatocellular Carcinoma Risk After HCV SVR: A Multicentre Cohort Study. (2026/08/01) ♡
• Differing Epidemiology of Chronic Hepatitis C Infection, Treatment, and Outcomes Among Migrants and Australian-Born Patients. (2026/08/01) ♡
• HCV-Specific T-Cell Recovery After a Year of SVR Following DAA Therapy. (2026/08/01) ♡
• Advanced HIV Presenting With Pancytopenia and HLH-Like Hyperinflammation Secondary to Disseminated Talaromycosis: A Case Report. (2026/07/29) ♡
• Diagnosis, Management, and Outcome of Antituberculous Drug-Induced Liver Injury in a Low-Resource Setting: A Case Report. (2026/07/29) ♡
• Factors influencing hepatitis C treatment initiation in a high-prevalence Brazilian state. (2026/07/20) ♡
• Association of p-glycoprotein and bile salt export pump gene polymorphisms with advanced liver disease in hepatitis C virus infected patients. (2026/07/20) ♡
• Association of IL-10 (rs1800896) and TLR3 (rs1879026) polymorphism with progression of hcv-related liver disease and hepatocellular carcinoma in Egyptian patients. (2026/07/18) ♡
• Baseline and post-treatment fibrosis-4 scores to predict hepatocellular carcinoma after direct-acting antiviral therapy. (2026/07/17) ♡
• Meta-analysisiAll studies on one question combined and calculated together. This is the strongest form of research that exists: a single loose study can be coincidence, dozens together much less so. The label says something about the design, not about the outcome — which can also be that something does NOT work. Efficacy and Long-Term Outcomes of Direct-Acting Antivirals in Patients with Hepatitis C Virus-Related Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis. (2026/07/15) ♡
• Systematic reviewiAll research on one question is searched according to fixed rules and compared side by side, so that no studies with poor outcomes are missed. Serum M2BPGi as a predictor of hepatocellular carcinoma development in chronic hepatitis B and C: a systematic review and meta-analysis. (2026/07/15) ♡
• Serum Gremlin 1 Remains Elevated Following Successful Direct-Acting Antiviral Therapy for Chronic Hepatitis C. (2026/07/14) ♡
• CD96 marks a phenotypically distinct checkpoint-associated HCV-specific CD8+ T-cell subset featuring memory-associated states. (2026/07/13) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Are Direct-Acting Antivirals Effective and Safe for Hepatitis C Patients with Arterial Hypertension? Evidence from a Large Retrospective Real-World Study. (2026/07/12) ♡
• Integrated deep learning and multi-scale modeling for the discovery of pan-genotypic HCV NS5B polymerase inhibitors. (2026/07/11) ♡
• Barriers and facilitators to hepatitis C patient engagement: Interview study with general practitioner champions in England. (2026/07/10) ♡
• Ulceronecrotic Plaques, Patchy Scalp Alopecia and Visual Disturbance in a 46-Year-Old Man. (2026/07/07) ♡
• Contact tracing for hepatitis C: perspectives of people with experience of substance use and hepatitis C on intervention acceptability. (2026/07/04) ♡
• Projected health benefits and cost offsets from the United States National Hepatitis C Elimination Initiative. (2026/07/02) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Pulmonary Complications in Cirrhosis: Current Concepts and Clinical Perspectives. (2026/07/02) ♡
• Development and validation of a multiplexed targeted HILIC-HRMS assay for quantitative analysis of hepatocellular carcinoma circulating biomarkers. (2026/07/01) ♡
• Phase 3 studyiResearch in a large group of patients, the final step before a treatment can be approved. What comes out here carries significant weight. Population Pharmacokinetic Analysis of Glecaprevir and Pibrentasvir in Pediatric Patients ≥ 3 to < 18 Years of Age with Genotypes 1-6 Chronic Hepatitis C Virus (HCV) Infection. (2026/07/01) ♡
• Validation of Risk Models for Predicting Post-SVR HCC in Real-World Surveillance Across Global Geographic Regions. (2026/07/01) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Direct Acting Antivirals Before Surgical Resection of HCV Related HCC: Impact on Tumour Pathology and Outcomes. (2026/07/01) ♡
• Cardiac MRI Identifies Subclinical Myocardial Tissue Abnormalities in Individuals With Hepatitis C Regardless of Myocardial Damage Markers or Fibrosis Stage. (2026/07/01) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Management of extensive portal vein thrombosis in adult living donor liver transplantation: the first case report from Indonesia. (2026/07/01) ♡
• Direct-Acting Antiviral Therapy and Hepatocellular Carcinoma in Captive Chimpanzees With Long-Standing Chronic Hepatitis C Virus Infection. (2026/07/01) ♡
• Defensins (HAD-1/HBD-1) as novel immune biomarkers in chronic hepatitis C: Association with inflammatory and antiviral cytokines and ROC-based diagnostic accuracy. (2026/07/01) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. The Impact of Achieving Sustained Viral Response with Direct Antiviral Agents in in HCV/HIV Co-infected Patients. (2026/07/01) ♡
• Lipidomics of HIV/HCV-related liver decompensation: association between plasma lipid depletion and immune dysregulation. (2026/06/30) ♡
• TNF-α is associated with low phase angle in male patients with chronic hepatitis C. (2026/06/30) ♡
• Chronic Viral Hepatitis with Concurrent MASLD: Dual Etiology Challenges. (2026/06/25) ♡
• Risk assessment and mitigation of hepatitis C virus RNA carryover contamination in a reflex testing algorithm. (2026/06/25) ♡
• Direct-acting antiviral therapy is associated with a reduced risk of selected immune-mediated inflammatory diseases in chronic hepatitis C infection: A real-world cohort study. (2026/06/25) ♡
• Interferon-induced interstitial lung disease: a rare adverse effect induced by pegylated interferon-alpha in a patient with chronic hepatitis B-case report. (2026/06/19) ♡
• Long-Term Risk Trajectories of Diabetes Differ After Direct-Acting Antiviral and Interferon Therapy in Chronic Hepatitis C: A Real-World Cohort Study. (2026/06/15) ♡
• Treatment guidelineiAn official agreement between doctors about how this disease should be treated. This is not a single study but the conclusion of an entire medical field. [Chinese guideline for the chemotherapy of multidrug-resistant/rifampicin-resistant tuberculosis (2026 edition)]. (2026/06/12) ♡
• Hepatitis C treatment uptake among incarcerated people in Norway, 2018-2019. (2026/06/12) ♡
• Time to viral load suppression with 8-week versus 12-week ravidasvir/sofosbuvir regimens among chronic hepatitis C patients in Malaysia: a non-inferiority, randomized clinical trial. (2026/06/11) ♡
• Higher Incidence of Hepatocellular Carcinoma in Suppressed Hepatitis B Cirrhosis Compared With Cured Hepatitis C Cirrhosis. (2026/06/09) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Chronic Hepatitis C Treatment Failure With Crushed Sofosbuvir/Velpatasvir in a Patient With Total Parenteral Nutrition-dependent Short Bowel Syndrome. (2026/06/01) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. HCV-related cryoglobulinemic vasculitis (mixed cryoglobulinemia syndrome) in the era of direct-acting antivirals: A 10-year experience from Italian tertiary referral centers. (2026/06/01) ♡

↑ Back to top

codex.care does not provide medical advice. Always discuss symptoms, medication, and treatment choices with your own healthcare provider.